1. Home
  2. SNDX vs CHCO Comparison

SNDX vs CHCO Comparison

Compare SNDX & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.31

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$126.20

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
CHCO
Founded
2005
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
SNDX
CHCO
Price
$19.31
$126.20
Analyst Decision
Strong Buy
Hold
Analyst Count
13
2
Target Price
$38.69
$132.50
AVG Volume (30 Days)
1.5M
83.0K
Earning Date
04-30-2026
04-23-2026
Dividend Yield
N/A
2.87%
EPS Growth
11.56
13.18
EPS
N/A
2.20
Revenue
$172,352,000.00
N/A
Revenue This Year
$107.19
$5.16
Revenue Next Year
$41.88
$3.12
P/E Ratio
N/A
$57.36
Revenue Growth
627.84
N/A
52 Week Low
$8.59
$113.21
52 Week High
$25.59
$133.59

Technical Indicators

Market Signals
Indicator
SNDX
CHCO
Relative Strength Index (RSI) 53.41 54.11
Support Level $19.28 $120.54
Resistance Level $22.40 $129.69
Average True Range (ATR) 0.82 2.69
MACD 0.25 0.04
Stochastic Oscillator 75.74 52.91

Price Performance

Historical Comparison
SNDX
CHCO

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

Share on Social Networks: